Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT06977698

Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery

Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery — Recruiting • Oncology • NCT06977698.

📅 30 Jul 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06977698
Sponsor
University of Nottingham
Start
2023-10-01
ClinicaliQ Trial Snapshot
  • Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery — Recruiting • Oncology • NCT06977698.
  • What is being tested: Novel dual optical imaging systems combining OCT-Raman spectroscopy (for lumpectomy specimens) and autofluorescence-Raman spectroscopy (for sentinel lymph nodes) to provide real-time, high-resolution intra-operative detection of positive surgical margins and lymph node involvement in breast cancer surgery.
  • Patient eligibility overview: Women undergoing breast-conserving surgery (lumpectomy) with sentinel lymph node biopsy for breast cancer, assessed for intra-operative specimen analysis without requiring additional patient procedures or extended operative time.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

In this project, the investigators will develop novel optical coherence tomography (OCT)-Raman spectroscopy and autofluorescence (AF)-Raman spectroscopy systems based on a selective sampling approach optimised for high-resolution analysis of whole lumpectomy specimens and sentinel lymph node (SLN) biopsies, respectively. The aim of using optical coherence tomography is not to detect cancer directly, but rather to identify adipose tissue so that large adipose regions can be excluded from subsequent Raman spectroscopy measurements. Although OCT has limited ability to distinguish tumour tissue from the surrounding normal stroma, adipose tissue exhibits a distinctive…

Eligibility Snapshot
  • * Patients undergoing breast surgery wide local excision (WLE). * Able to give informed consent. * Any age.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
Pope pictured for first time since surgery and cancer diagnosis
Oncology · BBC Health · 16 Oct 2026
Pope Francis underwent lung cancer surgery at Gemelli Hospital in Rome; public appearance marks recovery milestone following diagnosis First photographic evidence post-operatively…
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines of anti-HER2 treatment
Oncology · 20 Oct 2026
Trastuzumab deruxtecan is recommended as an option for HER2-positive unresectable or metastatic breast cancer only after 1 or more prior lines of…
View guideline →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Clinical Brief
‘Quick skin cancer pathway the best birthday gift’
Oncology · BBC Health · 09 Sep 2026
Key Takeaways for Clinical Practice Early referral through skin cancer fast-track pathways enables rapid diagnosis and treatment, improving outcomes for melanoma patients
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →